Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Earnings Results, Misses Expectations By $0.12 EPS

Key Points

• Vanda Pharmaceuticals reported a quarterly loss of ($0.46) EPS, missing expectations by ($0.12) and also experiencing lower revenue of $52.59 million compared to the anticipated $54.77 million.
• The company updated its FY 2025 guidance, indicating potential shifts in financial outlook for investors.
• Recently, Vanda's stock price decreased to $4.19, down from a 52-week high of $5.56, reflecting investor sentiment following the earnings report.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.12), Zacks reports. The business had revenue of $52.59 million during the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. Vanda Pharmaceuticals updated its FY 2025 guidance to EPS.

Vanda Pharmaceuticals Price Performance

NASDAQ VNDA traded down $0.07 on Friday, hitting $4.19. 766,997 shares of the stock were exchanged, compared to its average volume of 520,925. The business's fifty day moving average is $4.64 and its 200 day moving average is $4.54. Vanda Pharmaceuticals has a 52 week low of $3.81 and a 52 week high of $5.56. The company has a market capitalization of $246.93 million, a PE ratio of -3.71 and a beta of 0.68.

Analyst Ratings Changes

VNDA has been the topic of a number of research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Wall Street Zen lowered shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Saturday.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 7,000 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $4.59, for a total value of $32,130.00. Following the transaction, the director directly owned 97,082 shares of the company's stock, valued at $445,606.38. This represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the company's stock in a transaction dated Wednesday, May 21st. The stock was bought at an average cost of $4.40 per share, for a total transaction of $44,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,325,731 shares of the company's stock, valued at approximately $10,233,216.40. This trade represents a 0.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 10.00% of the company's stock.

Hedge Funds Weigh In On Vanda Pharmaceuticals

An institutional investor recently raised its position in Vanda Pharmaceuticals stock. Millennium Management LLC increased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 220.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,139,591 shares of the biopharmaceutical company's stock after acquiring an additional 1,470,898 shares during the quarter. Millennium Management LLC owned about 3.63% of Vanda Pharmaceuticals worth $9,821,000 as of its most recent filing with the SEC. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.